ID17051A - Komposisi farmasi yang terdiri dari mirtazapine dan satu atau lebih inhibitor pengambilan kembali serotonin pilihan - Google Patents

Komposisi farmasi yang terdiri dari mirtazapine dan satu atau lebih inhibitor pengambilan kembali serotonin pilihan

Info

Publication number
ID17051A
ID17051A IDP972117A ID972117A ID17051A ID 17051 A ID17051 A ID 17051A ID P972117 A IDP972117 A ID P972117A ID 972117 A ID972117 A ID 972117A ID 17051 A ID17051 A ID 17051A
Authority
ID
Indonesia
Prior art keywords
mirtazapine
serotonin
options
taking back
composition consist
Prior art date
Application number
IDP972117A
Other languages
English (en)
Indonesian (id)
Inventor
Victor Johanes Nickolson
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID17051(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of ID17051A publication Critical patent/ID17051A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDP972117A 1996-06-19 1997-06-19 Komposisi farmasi yang terdiri dari mirtazapine dan satu atau lebih inhibitor pengambilan kembali serotonin pilihan ID17051A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201703 1996-06-19

Publications (1)

Publication Number Publication Date
ID17051A true ID17051A (id) 1997-12-04

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP972117A ID17051A (id) 1996-06-19 1997-06-19 Komposisi farmasi yang terdiri dari mirtazapine dan satu atau lebih inhibitor pengambilan kembali serotonin pilihan

Country Status (24)

Country Link
US (1) US5977099A (enExample)
JP (2) JP4925074B2 (enExample)
KR (1) KR100481254B1 (enExample)
CN (1) CN1132581C (enExample)
AR (1) AR007609A1 (enExample)
AT (1) ATE213159T1 (enExample)
AU (1) AU727851B2 (enExample)
BR (1) BR9703624A (enExample)
CA (1) CA2208199C (enExample)
CZ (1) CZ290691B6 (enExample)
DE (1) DE69710390T2 (enExample)
DK (1) DK0813873T3 (enExample)
ES (1) ES2172744T3 (enExample)
HU (1) HU225534B1 (enExample)
ID (1) ID17051A (enExample)
IL (1) IL121076A (enExample)
NO (1) NO313177B1 (enExample)
NZ (1) NZ328113A (enExample)
PL (1) PL188520B1 (enExample)
PT (1) PT813873E (enExample)
RU (1) RU2181287C2 (enExample)
SG (1) SG60073A1 (enExample)
TR (1) TR199700522A2 (enExample)
ZA (1) ZA975335B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6303595B1 (en) * 1997-11-14 2001-10-16 Akzo Nobel N.V. Use of mirtazapine for treating sleep apneas
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
EP1178805A4 (en) * 1999-04-19 2004-11-24 Teva Pharma NOVEL SYNTHESIS AND CRYSTALLIZATION OF PIPERAZINE-CONTAINING COMPOUNDS
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
HUP0204050A3 (en) * 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
EP1656937A1 (en) * 2000-02-11 2006-05-17 Akzo Nobel N.V. The use of mirtazapine for the treatment of sleep disorders
WO2002036113A1 (en) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE60224078T2 (de) * 2001-02-12 2008-12-04 N.V. Organon Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
CA2479218A1 (en) * 2002-03-21 2003-10-02 Martin C. Hinz Serotonin and catecholamine system segment optimization technology
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
AU2003274608A1 (en) * 2002-11-07 2004-06-07 Sunil Sadanand Nadkarni Process for preparation of polymorphic form of sertraline hydrochloride
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
AU2003295235B2 (en) * 2002-12-27 2008-06-19 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
BRPI0407619A (pt) * 2003-02-21 2006-03-01 Martin C Hinz tecnologia de otimização de segmento de sistema serotonina e catecolamina
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
ES2639579T3 (es) 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
ES2426915T3 (es) 2003-09-10 2013-10-25 Brentwood Equities Ltd. Diastereoisómeros de 4-ariloxi-3-hidroxipiperidinas
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
RU2283097C2 (ru) * 2004-11-16 2006-09-10 Эльвира Ивановна Белобородова Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
EP2292269A3 (en) * 2004-11-19 2011-08-10 N.V. Organon Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AR063959A1 (es) 2006-11-09 2009-03-04 Orexigen Therapeutics Inc Formulaciones farmaceuticas en capas
CN101573103A (zh) 2006-11-09 2009-11-04 奥雷西根治疗公司 用于施用重量减轻药物的单位剂量包装和方法
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8768578B2 (en) 2009-06-09 2014-07-01 Sumitomo Heavy Industries, Ltd. Hybrid excavator and method of controlling hybrid excavator
KR101414012B1 (ko) * 2009-11-13 2014-07-01 주식회사 녹십자 아릴피페라진-함유 퓨린 유도체 및 그의 용도
KR20120124423A (ko) 2010-01-11 2012-11-13 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
RS67076B1 (sr) 2012-06-06 2025-08-29 Nalpropion Pharmaceuticals Llc Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
EP0431663B1 (en) * 1989-12-06 1994-01-12 Akzo Nobel N.V. Stabilized solutions of psychotropic agents
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
WO1999017803A1 (en) * 1997-10-03 1999-04-15 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug

Also Published As

Publication number Publication date
CZ187097A3 (cs) 1998-01-14
AU2612997A (en) 1998-01-08
BR9703624A (pt) 1998-09-01
ATE213159T1 (de) 2002-02-15
NO313177B1 (no) 2002-08-26
JP4925074B2 (ja) 2012-04-25
NZ328113A (en) 1999-09-29
TR199700522A3 (tr) 1998-01-21
CZ290691B6 (cs) 2002-09-11
HU9701068D0 (en) 1997-08-28
MX9704579A (es) 1998-07-31
US5977099A (en) 1999-11-02
ZA975335B (en) 1998-01-26
PL188520B1 (pl) 2005-02-28
ES2172744T3 (es) 2002-10-01
TR199700522A2 (xx) 1998-01-21
RU2181287C2 (ru) 2002-04-20
AU727851B2 (en) 2001-01-04
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
NO972816D0 (no) 1997-06-18
HK1006081A1 (en) 1999-02-12
CN1132581C (zh) 2003-12-31
HUP9701068A2 (hu) 1998-08-28
CA2208199C (en) 2006-10-24
PT813873E (pt) 2002-06-28
AR007609A1 (es) 1999-11-10
DE69710390D1 (de) 2002-03-21
PL320628A1 (en) 1997-12-22
IL121076A (en) 2000-10-31
CN1173330A (zh) 1998-02-18
JP2009137970A (ja) 2009-06-25
HUP9701068A3 (en) 2000-07-28
JPH1067663A (ja) 1998-03-10
KR980000447A (ko) 1998-03-30
NO972816L (no) 1997-12-22
DE69710390T2 (de) 2002-08-14
CA2208199A1 (en) 1997-12-19
KR100481254B1 (ko) 2005-09-12
DK0813873T3 (da) 2002-05-27
SG60073A1 (en) 1999-02-22

Similar Documents

Publication Publication Date Title
ID17051A (id) Komposisi farmasi yang terdiri dari mirtazapine dan satu atau lebih inhibitor pengambilan kembali serotonin pilihan
ID27394A (id) Kombinasi farmasi yang mengandung inhibitor cox-2 dan inhibitor inos
NO975245D0 (no) Heterocykluser som inhibitorer av laukocyttadhesjon og VLA-4-antagonister
NO982809D0 (no) Prolegemidler av tombin-inhibitorer
NO993717D0 (no) Anvendelse av gastrointestinale lipase-inhibitorer
FI971412L (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä
NO995802L (no) Anvendelse av oljelegemer
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
ID17316A (id) Komposisi aditif untuk pembawa bahan bermanfaat dan komposisi batang yang mengandung aditif tersebut
BR1100403A (pt) Composto e composição farmacêutica de inibidores de cox-2
DE69930351D1 (de) Klebstoffzusammensetzung und Klebeschicht
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
NO20000268D0 (no) Anvendelse av Lactobacillus for reduksjon av fibrinogen nivå
NO20001979D0 (no) Anvendelse av inhibitorer av renin-angiotensin-systemet
DE69815547D1 (de) Abrasionsbeständige tinenzusammensetzungen und verwendungsverfahren
PT927183E (pt) Inibidores espirociclicos de metaloproteases
IL133490A0 (en) New amidino derivatives and their use as thrombin inhibitors
NO20003256L (no) ACE inhibitor-MMP inhibitor kombinasjoner
ATE240733T1 (de) Kombination von 5-ht wiederaufnahme-inhibitoren und h5-ht 1b antagonisten oder partiellen agonisten
ZA988469B (en) Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors
EE9900524A (et) N-triasolüül-2-indoolkarboksamiidid ja nende kasutamine CCK-A agonistidena
NO985116D0 (no) Sammensetning som omfatter en KATP kanalhemmer for anvendelse i behandling av hemoragisk sjokk
ID24810A (id) Turunan-turunan isoquinolin tersubstitusi dan penggunaannya sebagai anti-kejang
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused
ID23163A (id) Turunan-turunan piridina dan komposisi-komposisi farmasi yang mengandungnya